KR910009956B1 - Process for preparation of benzimidazol derivatives - Google Patents

Process for preparation of benzimidazol derivatives Download PDF

Info

Publication number
KR910009956B1
KR910009956B1 KR1019890015157A KR890015157A KR910009956B1 KR 910009956 B1 KR910009956 B1 KR 910009956B1 KR 1019890015157 A KR1019890015157 A KR 1019890015157A KR 890015157 A KR890015157 A KR 890015157A KR 910009956 B1 KR910009956 B1 KR 910009956B1
Authority
KR
South Korea
Prior art keywords
formula
compound
cpd
benzimidazole
iii
Prior art date
Application number
KR1019890015157A
Other languages
Korean (ko)
Other versions
KR910007914A (en
Inventor
문순구
이관순
문영호
서강원
Original Assignee
한미약품공업 주식회사
임성기
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한미약품공업 주식회사, 임성기 filed Critical 한미약품공업 주식회사
Priority to KR1019890015157A priority Critical patent/KR910009956B1/en
Publication of KR910007914A publication Critical patent/KR910007914A/en
Application granted granted Critical
Publication of KR910009956B1 publication Critical patent/KR910009956B1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

A process for preparing a benzimidazole derivative of formula (I) comprises (a) reacting a cpd. of formula (II) with a cpd. of formula (III) in the presence of a base to obtain a phosphate ester cpd., (b) reacting the obtd. cpd. with benzimidazole-2-thiol of formula (IV), and (c) oxidizing the resulting cpd. to form (I). In the formulas, Y = O or S; R = C1-4 lower alkyl or opt. substd. phenyl. Pref. the cpd. of formula (III) is diethylchlorophosphate, diphenylchlorophosphate, diethylchlorothiophosphate or diphenylchlorothiophosphate. The base is selected from NaH or triethylamine. Cpd. (I) is useful as an antiulcer drug.

Description

벤즈이미다졸 유도체의 신규한 제조방법Novel Method for Preparing Benzimidazole Derivatives

본 발명은 항궤양제로서 유용한 다음 일반식(Ⅰ)로 표시되는 벤즈이미다졸 유도체의 새로운 제조방법에 관한 것이다.The present invention relates to a novel process for preparing benzimidazole derivatives represented by the following general formula (I), which is useful as an anti-ulcer agent.

Figure kpo00001
Figure kpo00001

상기 구조식(Ⅰ)로 표시되는 화합물은 오메프라졸이라는 일반명으로 명명된 화합물로서, 위궤양치료에 특히 탁월한 효과를 나타내는 것으로 보고되어 있다.The compound represented by the structural formula (I) is a compound named under the general name of omeprazole, and has been reported to have a particularly excellent effect in the treatment of gastric ulcer.

종래에는 다음구조식(Ⅰa)로 표시되는 벤즈이미다졸 유도체를 제조하는 방법이 여러 가지로 소개되어 있는바, 예를들면 영국특허 제1,500,043호 및 2,134,523호, 일본 특허공개 소 57-053,406호 및 57-039,622호 등에 개시되어 있으며, 이들 방법들을 대별해보면 다음의 세가지로 요약된다.Conventionally, various methods for preparing benzimidazole derivatives represented by the following structural formula (Ia) have been introduced, for example, British Patent Nos. 1,500,043 and 2,134,523, Japanese Patent Publication Nos. 57-053,406 and 57- 039,622, etc., and these methods can be summarized into the following three categories.

Figure kpo00002
Figure kpo00002

상기 구조식에서 n은 0 또는 1의 정수를 나타낸다.In the structural formula, n represents an integer of 0 or 1.

〈방법 Ⅰ〉<Method I>

다음구조식(A)의 피리딘 유도체를 다음구조식(B)의 치환된 벤즈이미다졸-2-티올과 반응시켜 다음구조식(Ⅰ′)의 화합물을 제조하는 방법A method for preparing a compound of formula (I ′) by reacting a pyridine derivative of formula (A) with a substituted benzimidazole-2-thiol of formula (B)

Figure kpo00003
Figure kpo00003

상기 구조식에서 X는 클로로, 브로모, 요오드, 파라톨루엔설포닐옥시 및 메탄설포닐옥시 등의 이탈기를 의미한다.In the above structural formula, X means leaving groups such as chloro, bromo, iodine, paratoluenesulfonyloxy and methanesulfonyloxy.

상기의〈방법 Ⅰ〉은 일반적으로 널리쓰이고 있는 방법이긴하나, 중간체인 구조식(A) 화합물이 불안정하여 쉽게 분해되기 때문에 반응의 수율이 저조한 단점이 있다.[Method I] is a widely used method, but has a disadvantage in that the yield of the reaction is poor because the compound of formula (A), which is an intermediate, is unstable and easily decomposed.

〈방법 Ⅱ〉<Method II>

다음구조식(C)의 치환된 2-피리딜메틸 티오포름산과 다음구조식(D)의 치환된 페닐렌디아민을 환화반응시켜 다음구조식(Ⅰ′) 화합물을 제조하는 방법A method for preparing the compound of formula (I ′) by cyclization of the substituted 2-pyridylmethyl thioformic acid of formula (C) with the substituted phenylenediamine of formula (D).

Figure kpo00004
Figure kpo00004

상기 〈방법 Ⅱ〉에서는 구조식(C) 화합물을 제조하는 방법이 매우 까다로우며, 또한 구조식(C) 화합물 자체가 매우 불안정하므로 목적화합물인 구조식(Ⅰ′) 화합물의 수율이 극히 저조한 단점이 있다.In Method II, a method of preparing the compound of formula (C) is very difficult, and the yield of the compound of formula (I ′), which is a target compound, is extremely low because the compound of formula (C) is very unstable.

〈방법 Ⅲ〉<Method III>

다음구조식(E)의 치환된 2-치환피리딘과 다음구조식(F) 화합물을 반응시켜 다음구조식(Ⅰ) 화합물을 제조하는 방법Method for preparing the compound of formula (I) by reacting the substituted 2-substituted pyridine of formula (E) with the compound of formula (F)

Figure kpo00005
Figure kpo00005

상기 구조식에서 X는 전술한 바와 같으며, M은 리튬나트륨, 칼륨 등의 알카리금속을 의미한다.In the structural formula X is as described above, M means an alkali metal, such as lithium sodium, potassium.

상기 〈방법 Ⅲ〉에서도 상기 구조식(F) 화합물의 제조가 까다로우며, 또한 그 화합물 자체가 매우 불안정하기 때문에 구조식(Ⅰ) 화합물의 수율이 저조한 단점이 있다.In <Method III>, too, the production of the compound of formula (F) is difficult and the yield of the compound of formula (I) is poor because the compound itself is very unstable.

상기한 방법 이외에도 대한민국 특허공고 제88-1714호, 89-1405호 및 89-1404호에 몇가지 제조방법이 제시되어 있으나 이역시 상기한 방법들과 같은 단점이 있다.In addition to the above-mentioned method, several manufacturing methods are disclosed in Korean Patent Publication Nos. 88-1714, 89-1405, and 89-1404, but there are disadvantages as described above.

이와같이 종래에 사용되어온 방법들은 그 반응물질의 제조가 몹시 까다롭거나, 또는 그 중간체 화합물이 매우 불안정하기 때문에 목적화합물의 제조수율이 극히 저조한 문제점이 있어서, 이에 대한 개선의 여지가 남아 있었다.Thus, the methods used in the prior art have a problem that the production of the target compound is extremely poor because the production of the reactant is very difficult or the intermediate compound is very unstable, and there is room for improvement.

이에 본 발명은 항궤양제로 유용하게 사용되고 있는 상기 구조식(Ⅰ)의 벤즈이미다졸 유도체를 제조함에 있어서, 종래방법에 비하여 일련의 제조공정이 보다 용이하면서도 목적화합물의 수율이 크게 개선되도록 하는 새로운 제조방법을 제공하는데 그 목적이 있는 것이다.Accordingly, the present invention provides a novel preparation method for producing a benzimidazole derivative of the above formula (I), which is usefully used as an anti-ulcer agent, so that a series of manufacturing processes are easier than the conventional methods, and the yield of the target compound is greatly improved. The purpose is to provide.

이하, 본 발명을 상세히 설명하면 다음과 같다.Hereinafter, the present invention will be described in detail.

본 발명은 구조식(Ⅰ)의 벤즈이미다졸 유도체를 제조함에 있어서, 다음구조식(Ⅱ)의 알코올을 염기존재하에 다음구조식(Ⅲ)의 포스페이트와 반응시켜 다음구조식(Ⅳ)의 포스페이트 에스테르화합물을 얻고, 여기에다 구조식(B)의 벤즈이미다졸-2-치올을 반응시켜 구조식(Ⅰ′) 화합물을 얻고, 이를 산화시켜 구조식(Ⅰ) 화합물을 제조하는 방법으로 이를 반응식으로 표시하면 다음과 같다.In the present invention, in preparing the benzimidazole derivative of formula (I), the alcohol of the following formula (II) is reacted with phosphate of the following formula (III) in the presence of a base to obtain a phosphate ester compound of the following formula (IV), In addition, benzimidazole-2-thiol of Structural Formula (B) is reacted to obtain Structural Formula (I ′), which is oxidized to produce Structural Formula (I).

Figure kpo00006
Figure kpo00006

상기 구조식들 중에서 Y는 산소 또는 황원자를 나타내며, R은 C1~4의 저급알킬 또는 치환되어 있어도 좋은 페닐기를 나타낸다.In the above structural formulas, Y represents oxygen or a sulfur atom, and R represents C 1-4 lower alkyl or a phenyl group which may be substituted.

본 발명에서 상기 구조식(Ⅳ) 화합물을 제조하기 위한 용매로는 알코올류를 제외한 극성용매, 즉 N, N-디메틸포름아미드, N, N-디메틸아세트아미드, 아세토니트릴, 디에틸에테르, 테트라하이드로퓨란, 1.4-디옥산등이 사용될 수 있으나, 이중 환상에테르인 테트라하이드로퓨란 및 1.4-디옥산이 가장 바람직하다.In the present invention, the solvent for preparing the compound of formula (IV) is a polar solvent except alcohols, that is, N, N-dimethylformamide, N, N-dimethylacetamide, acetonitrile, diethyl ether, tetrahydrofuran , 1.4-dioxane and the like can be used, but the most preferred are the bicyclic ethers tetrahydrofuran and 1.4-dioxane.

또한, 상기 구조식(Ⅲ) 화합물은 상기 구조식(Ⅱ)의 알코올에 대해 1~2당량을 사용할 수 있으나, 1.2당량 정도가 가장 바람직하다.In addition, the compound of formula (III) may be used in the amount of 1 to 2 equivalents based on the alcohol of the formula (II), about 1.2 equivalents is most preferred.

이때 사용되는 염기로는 트리에틸아민, N, N′-테트라메틸 에틸렌디아민(TMEDA), 트리메틸아민, 피리딘, 소듐하이드라이드(NaH), 소듐알콕사이드(NaOR1), 소듐아마이드(NaNH2), 리튬디이소프로필아미드(LDA), 노말부틸리튬(n-BuLi) 등이 사용될 수 있으나, Y가 산소원자인 경우에는 트리에틸아민, 트리메틸아민이, Y가 황원자인 경우에는 소듐하이드라이드(NaH)가 가장 바람직하다.The base used at this time is triethylamine, N, N'-tetramethyl ethylenediamine (TMEDA), trimethylamine, pyridine, sodium hydride (NaH), sodium alkoxide (NaOR 1 ), sodium amide (NaNH 2 ), lithium Diisopropylamide (LDA), normal butyllithium (n-BuLi), etc. may be used, but triethylamine, trimethylamine when Y is an oxygen atom, and sodium hydride (NaH) when Y is a sulfur atom Most preferred.

그리고, 반응온도는 0℃ 내지 환류온도에서 진행할 수 있으나 상온에서 진행시키는 것이 바람직하다.And, the reaction temperature may be carried out at 0 ℃ to reflux temperature, but it is preferable to proceed at room temperature.

한편, 상기 구조식(Ⅳ) 화합물은 수용액 또는 알코올등의 양자성용매(protic solvent)중에서도 안정하며 실리카겔 상에서도 거의 분해가 일어나지 않는다.On the other hand, the compound of formula (IV) is stable in a protic solvent (aqueous solution, such as an aqueous solution or alcohol) and hardly decomposes on silica gel.

또한, 상기 구조식(Ⅳ) 화합물은 분리하지 않고 한 용기내 반응(one-pot reaction)으로 다음반응에 이용할 수 있다.In addition, the compound of formula IV can be used for the next reaction in a one-pot reaction without separation.

본 발명에 있어서 상기 구조식(Ⅰ′) 화합물을 제조하기 위해서는 상기 구조식(Ⅳ)에다 구조식(B)의 화합물을 반응시키는데, 이때 사용되는 용매로는 메탄올, 에탄올, 이소프로필알코올, N, N-디메틸포름아미드, N, N-디메틸아세트아미드, 테트라하이드로퓨란, 1.4-디옥산 등이 사용될 수 있으나, 메탄올, 에탄올등의 알코올류가 가장 바람직하다.In the present invention, in order to prepare the compound of formula (I ′), the compound of formula (B) is reacted with the formula (IV), wherein the solvent used is methanol, ethanol, isopropyl alcohol, N, N-dimethyl. Formamide, N, N-dimethylacetamide, tetrahydrofuran, 1.4-dioxane and the like can be used, but alcohols such as methanol and ethanol are most preferred.

또한, 이반응에서 사용되는 염기로는 소듐알콕사이드(NaOR1)류가 가장 바람직하게 사용될 수 있으며, 환류온도에서 1~5시간이면 반응이 완결된다.In addition, sodium alkoxide (NaOR 1 ) may be most preferably used as the base used in this reaction, and the reaction is completed in 1 to 5 hours at reflux temperature.

이렇게 제조된 상기 구조식(Ⅰ′) 화합물에서 구조식(Ⅰ) 화합물을 제조하는 산화반응은 공지의 방법을 사용하며, 이때 산화제로서는 메타-클로로퍼벤조산, 퍼벤조산, 과산화수소, 소듐메타퍼요오데이트등을 사용할 수 있으나, 메타-클로로퍼벤조산 및 퍼벤조산등을 사용하는 것이 가장 바람직하다.The oxidation reaction for preparing the compound of formula (I) from the compound of formula (I ′) prepared in this manner uses a known method, wherein meta-chloroperbenzoic acid, perbenzoic acid, hydrogen peroxide, sodium metaperiodate, etc. Although it can be used, it is most preferable to use meta-chloroperbenzoic acid, perbenzoic acid, and the like.

이와같은 본 발명은 기존의 방법들과 비교하여 볼 때 새롭고도 안정한 포스페이트에스테르 중간체인 상기 구조식(Ⅳ) 화합물을 사용하여 목적하는 구조식(Ⅰ) 화합물을 고수율로 제조하는데 그 특징이 있는 것이다.The present invention is characterized by the high yield of the desired compound of formula (I) using the compound of formula (IV), which is a new and stable phosphate ester intermediate as compared to existing methods.

이하, 본 발명을 실시예에 의거하여 더욱 사세히 설명하면 다음과 같으며, 본 발명이 반드시 다음의 실시예에만 국한되는 것은 아니다.Hereinafter, the present invention will be described in more detail with reference to the following examples, and the present invention is not necessarily limited to the following examples.

[실시예 1]Example 1

[3, 5-디메틸-4-메톡시-2-(디페닐포스포릴옥시)메틸 피리딘의 제조][Preparation of 3, 5-dimethyl-4-methoxy-2- (diphenylphosphoryloxy) methyl pyridine]

3, 5-디메틸-4-메톡시-2-히드록시메틸피리딘(1.67g, 10mM)을 테트라하이드로퓨란(20ml)에 용해시키고 트리에틸아민(1.68ml, 12mM)을 가한다.3, 5-Dimethyl-4-methoxy-2-hydroxymethylpyridine (1.67 g, 10 mM) is dissolved in tetrahydrofuran (20 ml) and triethylamine (1.68 ml, 12 mM) is added.

상기 용액을 상온에서 10분간 교반시킨후 디페닐클로로포스페이트(2.49ml, 12mM)를 30분간에 걸쳐서 적가한다.After stirring the solution for 10 minutes at room temperature, diphenylchlorophosphate (2.49ml, 12mM) is added dropwise over 30 minutes.

그후 반응용액을 상온에서 2시간동안 교반시키고 반응이 완결되면 감압증류하여 용매를 제거한다. 그리고 나서 잔사에 증류수(30ml)를 가한후 디클로로메탄(2×30ml)으로 추출하고, 추출액을 합하여 포화탄산수소나트륨용액(30ml) 및 포화소금물(30ml)로 차례로 세척하여 탈수, 감압증류 시키면 무색오일상의 표제화합물을 얻는다.Thereafter, the reaction solution is stirred at room temperature for 2 hours, and when the reaction is completed, the solvent is removed by distillation under reduced pressure. Then, distilled water (30 ml) was added to the residue, followed by extraction with dichloromethane (2 × 30 ml). The extracts were combined and washed sequentially with saturated sodium hydrogen carbonate solution (30 ml) and saturated brine (30 ml). To obtain the title compound.

분석용 시료는 컬럼크로마토그래피(전개용매 에틸아세테이프/헥산=1:1)로 정제하여 얻는다.Analytical samples are obtained by purification by column chromatography (developing solvent ethyl acetate / hexane = 1: 1).

Figure kpo00007
Figure kpo00007

[실시예 2]Example 2

[3, 5-디메틸-4-메톡시-2-(디에틸치오포스포릴옥시)메틸 피리딘의 제조][Production of 3,5-dimethyl-4-methoxy-2- (diethylthiophosphoryloxy) methyl pyridine]

3, 5-디메틸-4-메톡시-2-히드록시메틸피리딘(3.34g, 20mM)을 테트라하이드로퓨란(30ml)에 용해시킨후 0℃로 냉각시키고 NaH(0.58g, 24mM)을 고체상태로 가한다.3, 5-dimethyl-4-methoxy-2-hydroxymethylpyridine (3.34g, 20mM) was dissolved in tetrahydrofuran (30ml), cooled to 0 ° C and NaH (0.58g, 24mM) in solid state. Add.

그후 반응용액의 온도를 상온으로 올려 2시간 반응시키고 용매를 감압증류하여 제거한다. 그리고나서 잔사에 증류수(40ml)를 가하고 에틸아세테이트(2×40ml)를 가하여 추출액을 합한다음, 포화소금물(40ml)로 세척한다. MgSO4를 가하여 탈수시키고 여과하여 여액을 감압증류시키면 무색오일상의 표제화합물을 얻는다.After that, the reaction solution was heated to room temperature and reacted for 2 hours, and the solvent was distilled off under reduced pressure. Then, distilled water (40 ml) was added to the residue, ethyl acetate (2 × 40 ml) was added, the extracts were combined, and washed with saturated brine (40 ml). MgSO 4 was added to dehydrate and filtered to distill the filtrate under reduced pressure to give the title compound as a colorless oil.

Figure kpo00008
Figure kpo00008

[실시예 3]Example 3

[5-메톡시-2-[(3.5-디메틸-4-메톡시피리딜메틸)티오]-(1H)-벤즈이미다졸의 제조][Preparation of 5-methoxy-2-[(3.5-dimethyl-4-methoxypyridylmethyl) thio]-(1H) -benzimidazole]

5-메톡시-2-머캅토벤즈이미다졸(5.94g, 33mM)과 NaOH(1.58g, 40mM)을 메탄올(100ml)에 혼탁시키고 가열환류시킨다.5-methoxy-2-mercaptobenzimidazole (5.94 g, 33 mM) and NaOH (1.58 g, 40 mM) are turbid in methanol (100 ml) and heated to reflux.

상기 용액에 실시예 2에서 제조한 3.5-디메틸-4-메톡시-2-(디에틸치오포스포릴옥시)메틸 피리딘(10.51g, 33mM)을 메탄올(30ml)에 녹인 용액을 30분동안 적가시킨다.To the solution was added dropwise a solution of 3.5-dimethyl-4-methoxy-2- (diethylthiophosphoryloxy) methyl pyridine (10.51g, 33mM) prepared in Example 2 in methanol (30ml) for 30 minutes. .

그후 반응용액을 2시간동안 가열환류시키고 상온으로 냉각하여 용매를 감압증류하여 제거시킨다. 그리고나서 잔사에 증류수(100ml)를 가하고 디클로로메탄(2×50ml)을 추출하여 탈수, 감압증류하면 목적하는 표제화합물을 담갈색 오일상으로 얻는다.Thereafter, the reaction solution was heated to reflux for 2 hours and cooled to room temperature to remove the solvent by distillation under reduced pressure. Then, distilled water (100 ml) was added to the residue, dichloromethane (2 × 50 ml) was extracted, dehydrated and distilled under reduced pressure to obtain the title compound as a light brown oil.

분석용 시료는 컬럼크로마토그래피(전개용매 에틸아세테이트/헥산=2:1)를 사용하여 얻는다.Analytical samples are obtained using column chromatography (developing solvent ethyl acetate / hexane = 2: 1).

Figure kpo00009
Figure kpo00009

[실시예 4]Example 4

[5-메톡시-2-[(3, 5-디메틸-4-메톡시피리딜메틸)티오]-(1H)-벤즈이미다졸의 제조][Preparation of 5-methoxy-2-[(3,5-dimethyl-4-methoxypyridylmethyl) thio]-(1H) -benzimidazole]

3, 5-디메틸-4-메톡시-2-히드록시메틸피리딘(1.67g, 10mM)을 테트라하이드로퓨란(20ml)에 용해시키고 트리에틸아민 1.68ml(12mM)를 가하고 상온에서 10분간 교반시킨다.3, 5-dimethyl-4-methoxy-2-hydroxymethylpyridine (1.67 g, 10 mM) is dissolved in tetrahydrofuran (20 ml), 1.68 ml (12 mM) of triethylamine is added and stirred at room temperature for 10 minutes.

상기 용액에 디페닐클로로포스페이트(2.49ml, 12mM)를 30분 동안에 걸쳐 적가하고 상온에서 2시간 반응시킨 후 생성된 결정을 여과하여 제거한다.Diphenylchlorophosphate (2.49ml, 12mM) was added dropwise to the solution over 30 minutes, reacted at room temperature for 2 hours, and the resulting crystals were filtered off.

한편, 다른 반응용기에 5-메톡시-2-머캅토벤즈이미다졸(1.80g, 10mM)과 NaOH(0.48g, 12mM)를 메탄올(20ml)에 혼탁시키고 가열 환류시키면서 앞에서 제조한 포스페이트 에스테르용액을 30분동안 적가한다.Meanwhile, in the other reaction vessel, 5-methoxy-2-mercaptobenzimidazole (1.80 g, 10 mM) and NaOH (0.48 g, 12 mM) were dissolved in methanol (20 ml) and heated to reflux to prepare the phosphate ester solution prepared above. Drop for 30 minutes.

그후 이를 1시간동안 가열 환류시킨후 상온으로 냉각시키고나서 pH를 중성으로(pH 7.0) 조절한후 용매를 감압증류하여 제거한다.Thereafter, the mixture was heated to reflux for 1 hour, cooled to room temperature, the pH was adjusted to neutral (pH 7.0), and the solvent was removed by distillation under reduced pressure.

그다음으로는 잔사에 증류수(50ml)를 가하고 디클로로메탄(2×50ml)으로 추출한후, 포화소금물(50ml)로 세척하여 MgSO4로 탈수시키고 감압증발시키면 담갈색의 표제 화합물을 오일상으로 얻는다.Then, distilled water (50 ml) was added to the residue, followed by extraction with dichloromethane (2 x 50 ml), followed by washing with saturated brine (50 ml), dehydration with MgSO 4 , and evaporation under reduced pressure to obtain a pale brown title compound as an oil phase.

Figure kpo00010
Figure kpo00010

[실시예 5]Example 5

[5-메톡시-2-[(3, 5-디메틸-4-메톡시피리딜메틸)술피닐]-(1H)-벤즈이미다졸의 제조][Preparation of 5-methoxy-2-[(3,5-dimethyl-4-methoxypyridylmethyl) sulfinyl]-(1H) -benzimidazole]

상기 실시예 3에서 제조한 5-메톡시-2-[(3, 5-디메틸-4-메톡시피리딜메틸)티오]-(1H)-벤즈이미다졸(0.83g, 2.52mM)을 클로로포름(10ml)에 용해시키고 온도를 -15℃~-20℃로 냉각시킨다.5-methoxy-2-[(3,5-dimethyl-4-methoxypyridylmethyl) thio]-(1H) -benzimidazole (0.83 g, 2.52 mM) prepared in Example 3 was added to chloroform ( 10 ml) and cooled to -15 ° C to -20 ° C.

상기 용액에 85% 메타-클로로퍼벤조산(0.52g, 2.52mM)을 클로로포름(5ml)에 녹인 용액을 동온도에서 30분간 적가한다.To the solution, a solution of 85% meta-chloroperbenzoic acid (0.52 g, 2.52 mM) in chloroform (5 ml) was added dropwise at the same temperature for 30 minutes.

그후 동온도에서 20분간 교반시킨다음 포화탄산수소나트륨용액(10ml)을 가하여 세척하고 클로로포름층을 MgSO4로 탈수시키고 여과하여 감압증발시킨다. 그리고나서 잔사에 아세톤(10ml)을 가하여 결정화시켜서 여과시키게되면 백색결정의 표제 화합물을 얻는다.After stirring for 20 minutes at the same temperature, saturated sodium hydrogen carbonate solution (10 ml) was added and washed. The chloroform layer was dehydrated with MgSO 4 , filtered and evaporated under reduced pressure. Then, acetone (10 ml) was added to the residue, crystallized and filtered to give the title compound as white crystals.

Figure kpo00011
Figure kpo00011

Claims (3)

벤즈이미다졸 유도체를 제조함에 있어서, 다음구조식(Ⅱ)의 알코올을 염기존재하에 다음구조식(Ⅲ)의 화합물과 반응시켜 다음구조식(Ⅳ)의 포스페이트에스테르 화합물을 얻고, 여기에다 다음 구조식(B)의 화합물을 반응시켜서 다음구조식(Ⅰ′) 화합물을 얻고 나서, 이 화합물을 산화시켜 다음구조식(Ⅰ)의 화합물을 제조하는 것을 특징으로 하는 벤즈이미다졸 유도체의 신규한 제조방법.In preparing the benzimidazole derivative, an alcohol of the following structural formula (II) is reacted with a compound of the following structural formula (III) in the presence of a base to obtain a phosphate ester compound of the following structural formula (IV), and a compound of the following structural formula (B) A reaction method for producing a benzimidazole derivative, characterized in that the compound of formula (I ') is obtained by oxidizing to form a compound of formula (I).
Figure kpo00012
Figure kpo00012
상기 식들중, Y는 산소 또는 황원자를 나타내고, R은 C1~4의 저급알킬 또는 치환되어 있어도 좋은 페닐기를 나타낸다.In the formulas, Y represents oxygen or a sulfur atom, and R represents C 1-4 lower alkyl or a phenyl group which may be substituted.
제1항에 있어서, 상기 구조식(Ⅲ)의 화합물로서는 디에틸클로로포스페이트, 디페닐클로로포스페이트, 디에틸클로로치오포스페이트 또는 디페니클로로치오포스페이트를 사용하여서 됨을 특징으로 하는 벤즈이미다졸 유도체의 제조방법.The method for producing benzimidazole derivatives according to claim 1, wherein diethylchlorophosphate, diphenylchlorophosphate, diethylchlorothiophosphate, or diphenylchlorothiophosphate is used as the compound of the formula (III). 제1항에 있어서, 상기 구조식(Ⅳ)의 화합물 제조시 사용되는 염기로서는 상기 구조식(Ⅲ)과 (Ⅳ)에서의 Y가 황원자인 경우에는 NaH를 사용하고, Y가 산소원자인 경우에는 트리에틸아민을 사용하여서 됨을 특징으로 하는 벤즈이미다졸 유도체의 제조방법.The base used in the preparation of the compound of the formula (IV) is NaH when Y in the formulas (III) and (IV) is a sulfur atom, and triethyl when Y is an oxygen atom. A method for producing a benzimidazole derivative, characterized by using an amine.
KR1019890015157A 1989-10-21 1989-10-21 Process for preparation of benzimidazol derivatives KR910009956B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019890015157A KR910009956B1 (en) 1989-10-21 1989-10-21 Process for preparation of benzimidazol derivatives

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019890015157A KR910009956B1 (en) 1989-10-21 1989-10-21 Process for preparation of benzimidazol derivatives

Publications (2)

Publication Number Publication Date
KR910007914A KR910007914A (en) 1991-05-30
KR910009956B1 true KR910009956B1 (en) 1991-12-07

Family

ID=19290893

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890015157A KR910009956B1 (en) 1989-10-21 1989-10-21 Process for preparation of benzimidazol derivatives

Country Status (1)

Country Link
KR (1) KR910009956B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100821165B1 (en) * 2006-03-10 2008-04-14 동우신테크 주식회사 Process for preparing lercanidipine hydrochloride

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100821165B1 (en) * 2006-03-10 2008-04-14 동우신테크 주식회사 Process for preparing lercanidipine hydrochloride

Also Published As

Publication number Publication date
KR910007914A (en) 1991-05-30

Similar Documents

Publication Publication Date Title
US4544750A (en) Certain pyridyl-N-oxide intermediates for the preparation of omeprazole
KR900012913A (en) Ether of 1-benzyl-3-hydroxymethyl-indazole with aliphatic 2-hydroxy acid
JPH03294264A (en) Production of optically active 3-hydroxypyrrolidine derivative
KR910009956B1 (en) Process for preparation of benzimidazol derivatives
US4769456A (en) Sulfenamide derivatives and their production
US4292431A (en) Process for the production of hydroxymethylimidazoles
EP1368338A1 (en) Method of preparing lansoprazole and its intermediate
KR950014792B1 (en) Benzimidazole derivatives and process for their preparations
KR910006983B1 (en) Process for the preparation of pyridine derivatives
JP3029901B2 (en) Method for producing 2-hydroxymethyl-4-methoxy-3,5-dimethylpyridine by a novel methoxy group introduction method
US4061668A (en) Process for the preparation of 2-(4-isobutylphenyl)-propiohydroxamic acid
KR920007270B1 (en) Method of preparing for pyridine
US2853497A (en) 6, 8-bis (hydrocarbon substituted mercapto) 5-hydroxycaprylic acids and delta-lactones thereof
JPH0717631B2 (en) Pyridinium derivative and method for producing the same
KR880002231B1 (en) Preparation process for pyridyloxy-phenol compound
KR940005019B1 (en) Process and production of pyrimidine derivatives
KR960002912B1 (en) Novel benzimidazole derivative
KR100311949B1 (en) Process for the preparation of 1-[(cyclopent-3-en-1-yl)methyl]-5-ethyl-6-(3,5-dimethylbenzoyl)-2,4-pyrimidinedione
KR920003691B1 (en) Process for the preparation of benzimidazole derivatives
KR100503267B1 (en) Method for the preparation of 2-acetyloxy-4-trifluoromethyl benzoic acid
KR940005017B1 (en) Process and production of pyrimidine derivatives
KR850000427B1 (en) Process for preparing pyrrole derivatives
JPH0522713B2 (en)
JP2005535708A (en) Improved synthesis of hydroxyazapyrone
JPS6322055A (en) Novel optically active hydroxyl ester

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
O035 Opposition [patent]: request for opposition

Free format text: OPPOSITION NUMBER: 001992001364; OPPOSITION DATE: 19920207